知镜 Cognispect · 医学文献与研究工作台

Metabolic dysfunction-associated steatotic liver disease after pancreaticoduodenectomy: Mechanisms, clinical impact, and therapeutic implications.

Theocharopoulos C, Ziogas IA, Papadakos SP, Varvoglis DN, Ziogas DC, Oba A, Pratap A, Del Chiaro M, Schulick R, Mungo B, Kontis E.
Metabolism: clinical and experimental · 2026-10-31 · PMID 42966495

文献摘要

Pancreaticoduodenectomy (PD) is associated with increasingly recognized long-term metabolic sequelae. Among these, metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging as a frequent but underappreciated phenomenon. Current evidence suggests that post-PD MASLD may represent a distinct metabolic phenotype driven predominantly by pancreatic exocrine and endocrine insufficiency, malnutrition, and altered gastrointestinal physiology rather than classical metabolic syndrome. These alterations may disrupt lipid metabolism, mitochondrial function, and hepatocellular homeostasis, promoting hepatic steatosis. Limited observational evidence has also associated post-PD MASLD with poorer survival, reduced chemotherapy tolerance, and challenges in postoperative imaging surveillance. Further characterization of its pathophysiology and clinical significance is needed to inform preventive and treatment strategies and optimize long-term outcomes. This review aims to summarize current evidence on the incidence, pathophysiology, clinical significance, and management of de novo MASLD following PD.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。